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Abstract:  
Dupuytren's disease is a fibroproliferative disorder that affects the hand's palm 
and eventually leads to loss of hand function. It is characterized by shortening of 
the palmar fascia and an increased myofibroblast presence in diseased tissue 
excised from Dupuytren's contracture surgery. Transforming growth factor-beta 
enhances the formation of structural elements and elevated expression of alpha-
smooth muscle actin in myofibroblasts. The objective of this study was to 





expected in response to transforming growth factor-beta to provide an unlimited 
supply of cells to investigate further the causes and treatments for Dupuytren's 
disease. 
A 3-dimensional collagen lattice model was used to study myofibroblast tension 
generation and contraction using an immortalized cell line derived from 
Dupuytren's disease (DP147+hTERT). In addition, DP147+hTERT was compared 
to its parental cell line derived from Dupuytren's contracture (DP147). We 
determined tension generation and contraction for both cell line types by 
measuring the decrease in the surface area of the collagen lattice over time. It was 
followed by lattice immunostaining to calculate the percentage of myofibroblasts 
and proliferation. In addition, cells were plated on coverslips (under maximum 
tension) then immunostained to determine differences in differentiation and 
proliferation between DP147 and DP147+hTERT. 
The results were encouraging for using the immortalized cell line for future studies 
on Dupuytren's disease; both cell lines showed increased myofibroblast 
differentiation in response to TGF-beta. Still, further investigations are required to 
understand differences in proliferation between DP147 and DP147+hTERT and its 
effect on the reliability of the immortalized cell line. 
	





Introduction:    
         
Dupuytren's Disease (DD) is characterized by the appearance of fibrotic lesions 
leading to flexion contractures of the fingers, followed by the loss of hand function 
(Tomasek 1999, Krause et al. 2011, Tripoli et al. 2016). In addition, DD is 
associated with thickening of the tissue underneath the skin (Tomasek 1999, Tse 
et al. 2004). This thickening occurs in the palm and extends to the fingers 
(Gabbiani et al. 1972, Tomasek 1999). DD treatment historically consists of 
surgical removal of the contracted tissues. High recurrence rates are associated 
with this type of surgery (Krause et al. 2011). At present percutaneous needle 
fasciotomy and collagenase injections in the cords are available alternatives to 
hand surgery (Hurst et al. 2009, van Rijssen et al. 2012, Tripoli et al. 2016); 
however, these procedures are not 100% effective and come with a high 
recurrence rate as well (Strömberg et al. 20016, Scherman et al. 2018). 
Researchers are working to maximize treatment strategies by investigating the 
causes. Several studies showed increased myofibroblast percentages in the tissue 
excised from Dupuytren's contracture (DC) surgery (Tse et al. 2004, Krause et al. 
2011).  
The myofibroblast is a specialized fibroblast responsible for generating contractile 
force associated with DD and characterized by a-smooth muscle actin (a-sma) 
within its contractile stress fibers (Desmouliere 1995, Vaughan et al. 2000, 





myofibroblasts cause wound contraction (Grinnell et al. 1999, Gabbiani 2003). 
During wound contraction, fibroblasts are responsible for the biosynthesis of new 
tissue matrix and differentiate to myofibroblasts (D'Urso and Kurniawan 2020).  
The cytokine transforming growth factor-beta (TGF-b) plays an essential role in 
tissue repair and wound healing (Border and Ruoslahti 1992, Desmouliere et 
al.1993, Midgley et al. 2013). TGF-b levels are found elevated after wound healing 
events, proving its importance to the wound healing process (Masur et al. 1996, 
Chipev et al. 2000, Razdan et al. 2018). TGF-b affects the conversion of fibroblasts 
to myofibroblasts; it increases myofibroblast differentiation by the elevated 
expression of a-sma and contractile force generation (Desmouliere 1995, 
Badalamente et al. 1996, Vaughan et al. 2000, Tomasek et al. 2002). In mammals, 
three isoforms, TGF-b1, -2, and -3, have been found (Yang et al. 1999). TGF-
b stimulates extracellular matrix deposition and fibroblast proliferation that 
characterizes DD (Kloen et al. 1995, D'Urso and Kurniawan 2020). Macrophages, 
fibroblasts, and several cell types may activate TGF-b during wound healing. In 
addition, TGF-b plays an essential role in other fibrotic diseases and cancer (Yang 
et al.1999).  
Telomeres are the ends of linear chromosomes; they contain long repetitive DNA 
sequences composed of TTAGGG, bound to specific proteins (Blackburn 1991, 
McChesney et al. 2000, Wright and Shay 2002). With each cell cycle, the 





far 3' end of the chromosome (Blackburn 1991, Brayan et al. 2000, McChesney et 
al. 2000, Wright and Shay 2002, Masutomi and Hahn 2003, Ramirez et al. 2003, 
Aubert and Lansdrop 2008). When telomeres become sufficiently short, the cell 
enters what is called senescence, which is irreversible growth arrest (Sager 1991, 
Brayan et al. 2000, Wright and Shay 2002). Telomerase helps stabilize telomere 
length in human reproductive cells, stem cells, and cancer cells by adding 
TTAGGG repeats onto the telomeres (Herbert et al. 1999, Zhang et al. 1999, Shay 
et al. 2001, Yatabe et al. 2002, Masutomi and Hahn 2003). Telomerase is the 
reverse transcriptase enzyme composed of two subunits, the protein catalytic 
subunit (TERT) and the template RNA subunit (TR) (Yatabe et al. 2002, Masutomi 
and Hahn 2003, Shay and Wright 2007, Hornsby 2007). Elevated telomerase 
activity has been discovered in immortalized, cancerous cells and in injured tissue 
and normal hematopoietic progenitor cells, endometrial cells, and the basal cells 
of skin and cervical keratinocytes (Hiyama et al. 1995, Funk et al. 2000, Shay et 
al. 2001, Razdan et al. 2018).  
Telomeres have an essential role in stabilizing the ends of the chromosomes, but 
they do not contain active genes. Instead, they contain long repetitive sequences 
and specific binding proteins, which form the unique T-loop structure at the end of 
the chromosome. Therefore, any changes in the length of the telomeres should 
not affect gene expression (O'Connor 2008). 
Telomere shortening during every cell cycle makes the life span of somatic cells 





cells enter a growth arrest state, which is known as replicative senescence (Aubert 
and Lansdrop 2008). Telomerase can reverse telomere shortening by the addition 
of the telomeric repeats. Telomeres and telomerase work together to maintain the 
ability of the cell to undergo cell division. Immortalization of human somatic cells 
by telomerase does not cause any growth transformation. However, telomerase 
extends the life span of cells without any alteration in functions. Telomerase is 
sufficient for fibroblast immortalization but not enough to cause malignant 
transformation (Morales et al. 1999). Jester et al. (2003) showed that TGF-
b induces myofibroblast differentiation in hTERT-immortalized human corneal 
fibroblast cell lines similar to their normal counterpart. According to these studies, 
we may predict that DP147+hTERT would differentiate similar to its parental cell 
line, DP147, in the presence or absence of TGF-b  because hTERT should not 
change the fibroblast phenotype; it just allows cell division to continue. 
Several studies showed that human TERT (hTERT) is expressed in different 
normal cells and tissues, including many epithelial cells, hematopoietic precursors, 
and spermatogonia (Masutomi and Hahn 2003). In addition, it is expressed more 
in fibroblasts versus myofibroblasts (Liu et al. 2006). Kalson et al. (2018) showed 
a significant association between telomere length and fibrotic condition and that 
telomere repair defects contribute to joint fibrosis. In lung injury and fibrosis, 
telomerase activity was induced in fibroblasts versus myofibroblasts. This induced 
activity can be inhibited with IL-4 and TGF-b (Liu et al. 2006, Razdan et al. 





expression of a-smooth muscle actin (a-sma), which indicated that there was 
myofibroblast differentiation (Liu et al. 2006, Tomasek et al. 2002). Based on these 
studies, we may predict that immortalized DP147+hTERT would not differentiate 
similar to DP147, its parental cell line, in the presence or absence of TGF-b.  
Therefore based on previous studies there are two conflicting hypotheses; 
telomerase inhibits myofibroblast differentiation (Liu et al. 2006), or telomerase 
does not inhibit myofibroblast differentiation (Morales et al. 1999, Jester et al. 
2003). Our goal is to test these hypotheses using a DD-derived cell line and 
determine whether telomerase has no effect on the myofibroblast phenotype or 
alters the phenotype. 
 
The Objective of the Study: 
The purpose of this study was to determine if hTERT-immortalized fibroblasts from 
DC would differentiate into myofibroblasts with and without TGF-b. Several studies 
showed that the myofibroblast is responsible for tissue contraction in DD (Gabbiani 
and Majno 1972, Tomasek and Rayan 1995, Tomasek et al.1999). We conducted 
in vitro studies to determine the ability of the immortal line of Dupuytren's cells to 
differentiate similar to their parental, non-immortalized cell line. Telomerase-
immortalized cell lines have been used to study several diseases (Lee et al. 2004) 
with unlimited potential for future studies. This study used telomerase-





ability to proliferate and differentiate using a coverslip culture assay, then study 
their ability to generate tension using collagen lattices. Coverslips are a reliable 
assay for studying the morphology of contractile cells (Tomasek and Rayan 1995). 
In addition, collagen lattices provide opportunities to understand the interaction 
between cells and their surroundings by providing a tissue-like environment (Bell 
et al. 1979, Tomasek et al. 1992, Vaughan et al. 2000, Grinnell 2003). We used 
the stress-relaxed collagen lattice to allow tension generation to produce the 
myofibroblast phenotype (Grinnell 1994, Vaughan et al. 2000).   
 
Materials and Methods: 
The study was conducted at Dr. Vaughan's Lab (HOH 253) in the biology 
department at the University of Central Oklahoma. The study was approved by 
UCO IRB (08077, 09027). 
Cell cultures:  
Two sets of cells were examined. One set was obtained from patients undergoing 
Dupuytren's contracture excision surgery (DP147), and another set was the 
hTERT immortalized cells from the same line (DP147+hTERT). These cells were 
cultured in Dulbecco's Modified Eagle's Medium (DMEM, Sigma) with 10% Fetal 
Bovine Serum (FBS) and penicillin, streptomycin, and amphotericin mixture 





were sub-cultured at least every seven days. The cells were determined immortal 
if they had a population-doubling rate (PD) beyond the non-immortalized cell. In 
addition, DNA fragment sequencing was performed by James Creecy (Dept. 
Biology, UCO) to determine whether DP147 and DP147+hTERT were derived 
from the same individual, thereby assuring that the immortalized cell is not a minor 
contaminant of a non-immortalized population (American Type Culture Collection 




   Cells were plated on glass coverslips (12mm round, Fisher Scientific) placed into 
wells in a 24 well spot plate (Falcon Multiwell). Cells at a concentration of 0.3x105 
were placed onto each coverslip. DP147 cells and DP147+hTERT were plated with 
and without TGF-b. Cell proliferation was determined by treating cells with 10 µM 
Edu 24 hours after incubation (5-ethynyl-2'-deoxyuridine) per 2 ml media for four 
hours before fixing (Vaughan et al. 2014). The Edu is a modified nucleotide that 
will be incorporated into replicating DNA. Detection of the incorporated nucleotide 
was done by reaction of the ethyl group of Edu with the fluorescent azide group of 
the click-chemistry. Edu staining is an effective method to measure cells during S-
phase. Unlike BrdU (5-bromo-2'deoxyuridine) labeling, Edu does not require harsh 





conclusion of cell culture, coverslips were washed with 1x PBS (Phosphate 
Buffered Saline). Then, coverslips were covered with a fixative (4% 
paraformaldehyde) for 20 minutes at room temperature in the fume hood. Next, 
coverslips were washed with 0.1 M phosphate buffer for 5 minutes, and this step 
was repeated two more times. Finally, coverslips were placed in 0.05 M Tris buffer 
for at least 30 minutes. Coverslips were stored in the refrigerator with PBS-Azide. 
Cells were stained using the inverted staining on the parafilm method (Tomasek 
and Rayan, 1995). Cells were washed with PBS for 5 minutes then stained for 
a-sma using the standard procedure. Cells were blocked with 1:10 goat serum for 
10 minutes. The primary antibody was 1:500 mouse anti-human a-sma (clone 
1A4, Sigma). Then we used Edu stain (Click-IT) for 30 minutes. Cells were washed 
three times with PBS. The primary antibody was labeled using the secondary 
antibody Goat anti-mouse rhodamine (Santa Cruz) at 1:200 dilution for 15 min in 
the dark. Dapi stain was added for an extra 30 minutes in the dark to stain DNA in 
cells. Cells were washed three times with PBS and then mounted with 80% 
glycerol/PBS (Vaughan et al. 2014). 
The stained coverslips were photographed using an inverted Olympus lX71 
microscope with a digital camera (DP72; Olympus) and software program 
(CelSens). A computerized image analysis program (ImageJ) was used to 
determine the positive immunostaining of the cells. The number of cells in the field 
was determined based on DAPI-positive nuclei (Vaughan et al. 2014). Cells were 





fibroblasts (PF), non-proliferative myofibroblasts (NPM), and proliferative 
myofibroblasts (PM) (Figure 1). At least 200 cells per set were counted, and each 
experiment was repeated three times. Two-way repeated-measures ANOVA 
(analysis of variance) was used to compare variation in myofibroblast 
differentiation between DP147 cells and DP147+hTERT cells and determine the 
effect of TGF-b on the two sets of cells. Repeated measures ANOVA was done to 
determine the variation in the percentage of myofibroblast proliferation and the 
percentage of fibroblast proliferation between DP147 cells and DP147+hTERT 
cells and between cells treated with TGF-b and cells that were not treated with 
TGF-b. 
 
Stress-relaxed collagen lattice model: 
 We used fibroblast populated collagen lattice (FPCL) to determine the differences 
in TGF-b induced contraction changes between DP147 and DP147+hTERT 
(Herwig and Vaughan 2014). Cells were sub-cultured, and the final cell 
concentration in the FPCL was 1.25 x 105 cells/ml. The collagen mixture included 
rat-tail collagen type I (Shelton and Summers Rada 2009), 0.1N NaOH, 10X 
EMEM (Eagle's Minimum Essential Medium), and 10X NaHCO3. Prepared 
collagen solution was mixed with the counted cell solution. The solution was mixed 
thoroughly and placed on ice. A 150µl collagen drop was plated in the center of a 





and another 24 lattices contained DP147+hTERT fibroblasts. Plates were gently 
placed in a 37oC incubator for one hour. Then 2 ml of media with or without TGF-
b was added to each plate. Collagen lattices were incubated for five days at 37oC 
to reach the maximum tension generation and then either released using a needle 
tip or pulsed with Edu for staining similar to the coverslip procedure. Digital images 
of the contracting cultures were captured using an inverted microscope (Olympus) 
with an attached camera (SPOT) (Herwig and Vaughan 2014). Images were 
captured before releasing the lattices and at 1, 2, 10, 30, and 60 minutes after the 
lattice was released from the bottom of the dish (Figure 2). A computerized image 
analysis program (ImageJ) was used to measure the FPCL area (mm2). Repeated 
measures ANOVA was run to compare the means of the four tested groups: 
DP147 with and without TGF-b and DP147+hTERT with and without TGF-b. 
Tukey's multiple comparisons followed the ANOVA.  
Collagen Lattice Staining: 
Replicate lattices that were not released and measured were prepared for staining 
similar to coverslips. Each lattice was covered with 4% paraformaldehyde for 20 
minutes at room temperature in the fume hood to preserve the protein structure 
and prepare the lattice for staining. Next, the collagen lattice was washed with 0.1 
M phosphate buffer for 5 minutes, and this step was repeated two more times. 
Then collagen lattice was cut into four pieces for staining. Collagen lattice staining 
was conducted to identify proliferation and differentiation similar to coverslips and 






Collagen lattice contraction: 
The contraction of the lattices and reduction in diameter over time provide an 
indirect measurement of tension generation (Tomasek et al. 1992). The repeated 
measures (ANOVA) was performed to determine the mean contraction and tension 
generation differences between collagen lattices with DP147 or DP147+hTERT. It 
was then followed with Tukey's test, which was completed and indicated no 
significant difference in the contraction of the collagen lattices containing DP147 
cells or the collagen lattice containing DP147+hTERT (F (1,5) = 0.454, p = 0.506). 
However, collagen lattices treated with TGF-b revealed more contraction in the 
collagen lattices with DP147 cells (F (1,5) = 23.413, p<0.0001) and the collagen 
lattices with DP147+hTERT cells (F (1,5) = 68.695, p<0.0001). The increase in the 
mean of contraction was statistically significant (Figure 3). 
Collagen lattice staining: 
Collagen lattice staining provides a direct correlation of structure to function, unlike 
coverslips. Proliferation and differentiation are associated with increased 
contraction/tension generation (Vaughan 2000). Therefore, we stained lattices to 
determine how proliferation and differentiation were correlated to contraction 
(Vaughan 2000). Repeated measures ANOVA was performed to determine the 
effect of TGF-b on the percentage of myofibroblasts for DP147 cells and 





and outliers (Figure 4). The results showed an increase in myofibroblast 
percentage in both DP147 cells (F (1,34) = 3.833, p = 0.058) and DP147+hTERT 
cells (F (1,34) = 0.055, p= 0.815) after TGF-b treatment, but that increase was not 
statistically significant (P> 0.05). Also, the results show that percentage of 
myofibroblasts was not significantly different between DP147 cells and 
DP147+hTERT cells (F (1,34) = 3.319, p = 0.077) (Figure 4, Figure 5). 
There was a significant increase in the percentage of myofibroblast proliferation in 
DP147+hTERT, comparing it with DP147 (F (1,34) = 4.547, p = 0.040). Treating 
the cells with TGF-b did not affect the percentage of myofibroblast proliferation in 
DP147 (F (1,34) = 0.201, p = 0.656) and DP147+hTERT (F (1,34) = 0.292, p = 
0.59) (Figure 6, Figure 7). There was no significant difference in the percentage of 
fibroblast proliferation in DP147 and DP147+hTERT. Also, treating cells with TGF-
b showed a significant increase in the percentage of fibroblast proliferation in 
DP147+hTERT (F (1,34) = 6.624, p = 0.014)) but not in DP147 (F (1,34) = 0.139, 
p = 0.710) (Figure 8, Figure 9). 
Coverslips staining: 
DP147+hTERT cells showed a significant increase in the percentage of 
myofibroblasts compared to DP147 cells. The repeated measures ANOVA was 
performed, and the results were significantly different between DP147+hTERT and 





a significant increase in myofibroblast percentage (p< 0.05) (Figure 10 and Figure 
11).   
The percentage of myofibroblast proliferation was determined, and results showed 
no difference between DP147 and DP147+hTERT (F (1,28) = 1.020, p = 0.321). 
Also, treating both cell types with TGF-b did not significantly affect the percentage 
of myofibroblast proliferation (Figure 12). Treating DP147 with TGF-b increased 
the percentage of fibroblast proliferation, but this increase was not statistically 
significant (F (1,28) = 1.563, p = 0.221) (Figure 13). 
 
Discussion: 
TGF-b, in addition to the mechanically stressed environment, is essential for the 
differentiation of fibroblasts into myofibroblasts in vitro (Tomasek et al. 2002). The 
focus of this research was to investigate the ability of hTERT-immortalized 
fibroblasts from DC to differentiate as expected in the presence of TGF-b, with the 
potential of conducting unlimited further studies and investigations. First, we used 
the fibroblast populated collagen lattice (FPCL) model to determine the TGF-b 
induced contraction differences between DP147 and DP147+hTERT (Herwig and 
Vaughan 2014). The collagen lattice model closely resembles what occurs in vivo; 
it provides a tissue-like environment to measure contraction at the tissue level 





We measured the contraction of the FPCL with DP147 cells and compared it to the 
results of DP147+hTERT (Figure 3). The lattice contraction and reduction of 
diameter provides a measurement of tension generation. The results showed no 
significant differences in the contraction in DP147 and DP147+hTERT lattices. In 
addition, both FPCL showed a substantial increase in contraction when treated 
with TGF-b (Figure 2, Figure 3). Therefore, we predicted that DP147 collagen 
lattices would increase myofibroblasts with TGF-b treatment, but we expected that 
DP147+hTERT, when treated with TGF-b, to show no increase in myofibroblast. 
Liu et al. (2006) showed that telomerase inhibits myofibroblast differentiation, and 
the loss of telomerase activity increases myofibroblast differentiation. However, 
our results showed that FPCL with DP147+hTERT increased contraction and 
myofibroblast differentiation when treated with TGF-b, same as the results of FPCL 
with DP147. Thus, our collagen lattice results support the null hypothesis, 
indicating no difference between DP147 and DP147+hTERT in differentiation and 
collagen lattice contraction and agree with Jester et al. (2003). 
The collagen lattice immunostaining with anti-smooth muscle alpha-actin is 
essential in determining the percentage of the differentiated myofibroblast. 
Collagen lattice immunostaining results showed that TGF-b increased the 
percentage of the myofibroblasts in both cell types, but the increase in 
myofibroblasts was not significantly different (P>0.05) (Figure 5). Thus, the 
collagen lattice stain results support the FPCL results. Furthermore, the increase 





expression of the a-sma, which increases the contractile force as shown in the 
FPCL (Vaughan et al. 2000).  
In addition, the coverslip results confirm that treating both types of cells (DP147 
and DP147+hTERT) increases the percentage of myofibroblast, the same as the 
FPLC results. Vaughan et al.'s 2000 results showed that using FPCL resembles 
what occurs in vivo; while cells on coverslips grow under maximum tension, cells 
in the collagen lattices grow under tension but not maximum tension. Due to these 
differences, the coverslips staining results could show differences when compared 
to collagen lattice results. 
DD is a fibroproliferative tissue rich in myofibroblasts (Tomasek et al. 1999, Tripoli 
et al. 2016). The proliferation of myofibroblasts is crucial for developing DD 
(Rehman et al. 2011). Therefore, it is essential to understand myofibroblast 
proliferation and differentiation as part of studying the mechanisms of developing 
this kind of palmar fibromatosis. Our collagen lattice results showed a significant 
increase in the percentage of myofibroblast proliferation in DP147+hTERT 
compared to DP147. Treatment with TGF-b did not significantly affect the 
proliferation of the myofibroblast in collagen lattice or the coverslips. However, the 
coverslips staining showed an increase in the percentage of fibroblast proliferation 
in DP147+hTERT more than DP147, not in the myofibroblast as in the collagen 
lattices results. As we mentioned before, growing the cells under maximum tension 
on a coverslip would affect the proliferation and differentiation potential (Vaughan 





The increase in the myofibroblast proliferation of the DP147+hTERT in collagen 
lattices compared to DP147 could be due to higher levels of telomerase in 
DP147+hTERT, which cause more proliferation in cells as what happens in tumor 
cells (Wright and Shay 2002). However, the DP147 cells used in this research were 
early in population doubling (PD), meaning they still had proliferation potential. 
Studies showed that telomeres in normal cells are variable in length (Ramirez et 
al. 2003, Martin-Kuiz et al. 2004); some have long telomeres, and some have short 
ones. Therefore, the DP147 cultures we used may have been heterogeneous; 
indeed, some cells may have been growth-arrested, which may have caused this 
reduced proliferation.  
The DP147+hTERT shows promising results based on the percentage of 
myofibroblasts and contraction. However, further investigations are required to 
determine the effectiveness of using this cell line and its resemblance to the cells 
extracted from DC to advance our knowledge about this disease and further 










Conclusions and Further Studies: 
Our investigations on the immortalized cell line of DD enhance the understanding 
of this disorder. We examined the effectiveness of using the immortalized cell line 
so that future studies are not limited to a finite number of cells available. This study 
has demonstrated that the immortalized cell line shows promising results when 
comparing cells extracted from DD (DP147) with the immortalized 
(DP147+hTERT) cells. Similarities in myofibroblast percentage and similarities 
with the effect of TGF-b on the increase in the myofibroblast percentage yielded 
encouraging results to use further the immortalized cell line in future investigations. 
Further investigations and experiments are required to understand better the 
differences in proliferation between DP147 and DP147+hTERT and the 
effectiveness of using this cell line to advance our understanding of the palmar 
fascia in DD. The question here is whether the proliferation and contraction of 
myofibroblasts in vitro is the same as in vivo. Furthermore, investigations and 
experiments on this disorder may require an animal model to understand the 










Figure 1: Coverslip immunostaining. Myofibroblast proliferation stain allows 
quantification of 4 cell types. For each field of view, images were collected using 
the blue (dapi-nuclei counterstain), the green (Edu-proliferation), and the red (a-
sma-differentiation). Four cell types were identified when the images were 
combined: non-proliferative fibroblast, proliferative fibroblast, non-proliferative 









Figure 2: DP147 and DP147+hTERT contract similarly in the presence or 
absence of TGF-b. Images of collagen lattices showing the change caused by 
the fibroblast contraction at 0, 1, 2, 10, 30, and 60 minutes after release. Four 
series of images are collagen lattices with DP147, DP147+TGF-b, 









Figure 3: Mean contraction of collagen lattices in the presence or absence of 
TGF-b. Fibroblast plated collagen lattices (FPCL) were used to measure the 
reduction in diameter over time as a measurement of tension generation. 
Collagen lattices treated with TGF-b showed more contraction for both DP147 



























Figure 4: Percentage of myofibroblast in the FPCL with DP147 cells and 
DP147+hTERT cells. Results showed no significant difference between DP147 
and DP147+hTERT in myofibroblast percentage (F (1,34) = 3.319, p = 0.077). 
Although, when treated with TGF-b, results showed an increase in the 
myofibroblast percentage in FPCL with DP147 and FPCL with DP147+hTERT, 

























Figure 5: Mean percentage of myofibroblasts in FPCL with DP147 cells and 
DP147+hTERT cells, treated with TGF-b, and was not treated with TGF-
b. Repeated measures ANOVA was performed, and results showed an increase 
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Figure 6: Percentage of proliferating myofibroblasts in collagen lattice. Results 
showed a significant increase in the percentage of myofibroblast proliferation in 
DP147+hTERT compared to DP147. Treatment with TGF-b showed an increase 


























Figure 7: Mean percentage of proliferating myofibroblasts in collagen lattice. No 
significant increase in the percentage of proliferating myofibroblasts when treated 
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Figure 8: Percentage of proliferating fibroblasts in collagen lattice. Treating cells 
with TGF-b significantly affected fibroblast proliferation in DP147+hTERT (F 
(1,34) =6.624, p=0.014). Results show no difference in the percentage of 

























Figure 9: Mean percentage of proliferating fibroblasts in collagen lattices with 
DP147 and DP147+hTERT. Results showed a significant increase in the 
percentage of proliferating fibroblasts in collagen lattices with DP147+hTERT 
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Figure 10: Mean percentage of myofibroblasts plated on the coverslips. A 
significant increase in the mean percentage of myofibroblasts when treated with 




























Figure 11: Percentage of myofibroblasts plated on the coverslips. Results 
showed a significant increase in the percentage of myofibroblasts when treated 






















Figure 12: Mean percentage of proliferating myofibroblasts on the coverslips. 
Treating DP147 and DP147+hTERT with TGFb did not statistically significantly 
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Figure 13: Mean percentage of fibroblast proliferation on the coverslips. Treating 
DP147 with TGF-b increased the percentage of fibroblast proliferation, but the 
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